- Report
- August 2026
- 189 Pages
Global
From €3142EUR$3,545USD£2,696GBP
€3491EUR$3,939USD£2,995GBP
- Report
- August 2026
- 181 Pages
Global
From €3141EUR$3,545USD£2,696GBP
€3491EUR$3,939USD£2,995GBP
- Report
- August 2026
- 110 Pages
Global
From €4209EUR$4,750USD£3,612GBP
- Report
- March 2026
- 177 Pages
Global
From €15947EUR$17,995USD£13,684GBP
- Report
- August 2025
- 192 Pages
Global
From €3142EUR$3,545USD£2,696GBP
€3491EUR$3,939USD£2,995GBP
- Report
- May 2024
- 134 Pages
Global
From €2658EUR$2,999USD£2,280GBP
€3544EUR$3,999USD£3,041GBP
- Report
- May 2025
- 134 Pages
Global
From €15947EUR$17,995USD£13,684GBP
- Report
- August 2026
- 50 Pages
Global
From €2348EUR$2,650USD£2,015GBP
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of immune disorders. It is used in combination with other drugs to treat HIV/AIDS, hepatitis B, and other immune disorders. It works by blocking the action of reverse transcriptase, an enzyme that is essential for the replication of HIV and other viruses. Emtricitabine is also used to prevent the transmission of HIV from mother to child during pregnancy.
Emtricitabine is available in both oral and injectable forms. It is generally well tolerated, with few side effects. Common side effects include nausea, headache, and fatigue. Serious side effects are rare, but can include liver damage and allergic reactions.
Emtricitabine is marketed by several pharmaceutical companies, including Gilead Sciences, Bristol-Myers Squibb, and Merck. It is also available in generic form from several generic drug manufacturers. Show Less Read more